FOLH1 and posterior cortical atrophy: It shall be noted that several PSMA-targeting BiTEs, includingAMG-212, AMG-160, MOR-209, CC-1, and JNJ-081, have been tested inpreclinical settings and/or entered clinical trials.52−55 While these drugs showed positive effects in targeting PCa, (pre)clinicaldata also highlighted challenges and adverse effects that need tobe addressed and mitigated to develop safe and efficacious immunotherapeuticsagainst PCa.